<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04062058</url>
  </required_header>
  <id_info>
    <org_study_id>LC2018L03</org_study_id>
    <nct_id>NCT04062058</nct_id>
  </id_info>
  <brief_title>A Phase II Study of Total Neoadjuvant Therapy for Locally Advanced Gastric Cancer</brief_title>
  <official_title>A Phase II Study of Total Neoadjuvant Therapy for Locally Advanced Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jing Jin, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Hope Run</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective, single arm phase II study is designed to evaluate the rate of pathologic
      complete response of neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy followed by
      surgery for locally advanced gastric adenocarcinoma
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 20, 2018</start_date>
  <completion_date type="Anticipated">September 21, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 21, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PCR rate</measure>
    <time_frame>6-8 months</time_frame>
    <description>Pathological response were classified into three grades.Grade I signifies that there is little shrinkage in the tumor; only mild regression in the tumor cells is observed under telemicroscope. Grade II shows gross reduction in size of the tumor and marked regression in the cancer cells microscopically, yet viable nests of cancer tissue are still visible. Grade III implies complete or almost total resolution of the tumor on exploration, and disappearance of the tumor tissue microscopically; only remnants of degenerated cancer cells can be seen (so-called ghost cancer cells).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute chemotherapy/Chemoradiotherapy toxicities</measure>
    <time_frame>6-8 months</time_frame>
    <description>chemotherapy toxicities are evaluated by NCI-CTC version 4.0 and radiotherapy toxicities are graded using the RTOG/EORTC Radiation Morbidity Scoring Schema.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>surgery complications</measure>
    <time_frame>6-8 months</time_frame>
    <description>During hospital stay and within the first 30 days after completion of surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor down-staging</measure>
    <time_frame>6-8 months</time_frame>
    <description>Down-staging was considered as any stage reduction between clinical and pathologic stage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>6-8 months</time_frame>
    <description>The surgical procedure was total or subtotal gastrectomy with recommended D2 lymphadenectomy 4-6 weeks after total neoadjuvant therapy.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">82</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Neoadjuvant Therapy</condition>
  <arm_group>
    <arm_group_label>Total Neoadjuvant Chemoradiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Total neoadjuvant chemoradiotherapy arm receives intensity-modulated neoadjuvant chemoradiotherapy (45Gy in 25 fractions) concurrently with oral S-1(40-60mg/m2, orally twice daily every weekday) followed by six cycles of SOX neoadjuvant chemotherapy and surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SIB-IMRT</intervention_name>
    <description>45Gy in 25 fractions using intensity-modulated radiotherapy to the radiation target</description>
    <arm_group_label>Total Neoadjuvant Chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1</intervention_name>
    <description>40-60mg/m2(according to patient's body surface area), orally twice daily every weekday concurrently with radiotherapy treatment</description>
    <arm_group_label>Total Neoadjuvant Chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOX</intervention_name>
    <description>SOX (S-1: 40~60mg, orally twice daily on days 1 to 14, oxaliplatin 130mg/m2 intravenously on day 1, 21 days per cycle)</description>
    <arm_group_label>Total Neoadjuvant Chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>Surgery, preferred D2 lymphadenectomy</description>
    <arm_group_label>Total Neoadjuvant Chemoradiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically proven locally advanced gastric adenocarcinoma in
             patients staged as cT3-4N+M0

          -  No distant metastasis in liver,lung,bone,central nervous system(CNS),no peritoneal
             transplantation

          -  No prior abdominal or pelvic radiotherapy

          -  Karnofsky performance status(KPS)â‰¥ 70, predictive life span no less than 6 months

          -  Patients must have normal organ and marrow function as defined below: Leukocytes:
             greater than or equal to 3,000 G/L; Platelets: greater than or equal to 100,000/mm3
             .Hemoglobin:greater than or equal to 10g/L .Total bilirubin: within normal
             institutional limits; AST/ALT: less than or equal to 1.5 times the upper limit;
             Creatinine within normal upper limits

          -  Informed consent

        Exclusion Criteria:

          -  Any prior chemotherapy or other cancer treatment prior to this protocol

          -  Patients with other cancer history except cervical carcinoma in situ and non-malignant
             melanoma skin cancer

          -  With any distant metastasis in liver,lung,bone,CNS,or peritoneal transplantation

          -  History of allergic reactions attributed to similar chemical or biologic complex to
             S-1 or Xeloda or Oxaliplatin

          -  Uncontrolled illness including, but not limited to, active infection, symptomatic
             heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness

          -  History of myocardial infarction within the past 6 months or history of ventricular
             arrhythmia

          -  History of prior radiation to the abdomen

          -  Pregnant or lactating females
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jing Jin, MD</last_name>
    <phone>+8613601365130</phone>
    <email>jingjin1025@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC)</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ning Li, MD</last_name>
      <phone>+8613810381399</phone>
      <email>lee_ak@163.com</email>
    </contact>
    <investigator>
      <last_name>Jinming Shi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>August 18, 2019</study_first_submitted>
  <study_first_submitted_qc>August 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2019</study_first_posted>
  <last_update_submitted>August 18, 2019</last_update_submitted>
  <last_update_submitted_qc>August 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Jing Jin, M.D.</investigator_full_name>
    <investigator_title>Chinese Academy of Medical Sciences and Peking Union Medical College</investigator_title>
  </responsible_party>
  <keyword>gastric cancer</keyword>
  <keyword>neoadjuvant chemoradiotherapy</keyword>
  <keyword>neoadjuvant chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

